Cargando…

Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report

Detalles Bibliográficos
Autores principales:	Rana, Ritika, Pratt, Guy, Cook, Mark, Drayson, Mark Trehane, Ramasamy, Karthik, Sadler, Ross, Zhu, Doreen, Connor, Thomas, Pinney, Jennifer Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258662/ https://www.ncbi.nlm.nih.gov/pubmed/34226245 http://dx.doi.org/10.1136/bmjoq-2020-001085

Ejemplares similares

Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report
por: Rana, Ritika, et al.
Publicado: (2018)

What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial
por: Behrens, Judith, et al.
Publicado: (2022)

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
por: Bowcock, Stella, et al.
Publicado: (2023)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Monoclonal gammopathy of increasing significance: time to screen?
por: Chen, Lucia Y., et al.
Publicado: (2022)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
por: Heaney, Jennifer L. J., et al.
Publicado: (2017)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity
por: Heaney, Jennifer L. J., et al.
Publicado: (2022)

Time of day of vaccination does not relate to antibody response to thymus-independent vaccinations
por: Whittaker, Anna C., et al.
Publicado: (2022)

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
por: Chicca, Ilaria J., et al.
Publicado: (2020)

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
por: Kolovos, Spyros, et al.
Publicado: (2019)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Validation of clinical‐grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly‐diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project
por: Lomas, Oliver C., et al.
Publicado: (2021)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
por: Weinberg, Olga K., et al.
Publicado: (2023)

Dissecting racial disparities in multiple myeloma—clues from differential immunoglobulin levels
por: Bunce, C. M., et al.
Publicado: (2020)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
por: Cook, Gordon, et al.
Publicado: (2020)

De novo variants in sporadic cases of childhood onset schizophrenia
por: Ambalavanan, Amirthagowri, et al.
Publicado: (2016)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

PReS-FINAL-2099: Assessing the standards of oral health in children and adolescents with juvenile idiopathic arthritis
por: Trehane, SJ, et al.
Publicado: (2013)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Multiple myeloma in the very elderly patient: challenges and solutions
por: Willan, John, et al.
Publicado: (2016)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
por: Drayson, Mark T, et al.
Publicado: (2019)

Biclonal myeloma in renal failure
por: NIKOLOVA-VLAHOVA, MILENA K., et al.
Publicado: (2020)

Short-, long-, and very long-term results of secondary anterior sphincteroplasty in 20 patients with obstetric injury
por: Haug, Helene Marie, et al.
Publicado: (2021)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I–III breast cancer
por: Smith, Amelia, et al.
Publicado: (2016)

De novo Synthesis of Chemical Defenses in an Aposematic Moth
por: Burdfield-Steel, Emily, et al.
Publicado: (2018)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_6iu390cr51br9a66av7vpaatrk